期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

替吉奥治疗晚期乳腺癌的研究进展 被引量：4

Progress on S-1 in the treatment of advanced breast cancer
下载PDF
导出
摘要 替吉奥(S-1)是第三代氟尿嘧啶衍生物的口服抗癌剂,毒副作用小、疗效确切、给药方便。在大量的临床试验及不断的临床应用中,其展示出对晚期乳腺癌(advanced breast cancer,ABC)治疗的良好效果,将来有望成为乳腺癌治疗的一线化疗药物。 S-1 is the third generation of fluorouracil derivative anti-cancer agent with small side effects ,efficacy ,and drug delivery is convenient .In a large number of clinical trials and continuous clinical application ,it showed the good effect for the treatment of advanced breast cancer ,which was expected to become the first-line chemotherapy drug for breast cancer treat-ment in the future .
作者 郑婷 钱其军
机构地区 福建医科大学第一临床医学院 第二军医大学附属东方肝胆外科医院生物治疗科病毒基因治疗实验室
出处 《药学实践杂志》 CAS 2015年第6期557-560,共4页 Journal of Pharmaceutical Practice
基金 国家科技重大专项(No.2013ZX10002-010-007)
关键词 替吉奥(S-1) 晚期乳腺癌 化疗药物 advanced breast cancer chemotherapy drug
分类号 R736.3 [医药卫生—肿瘤] R979.1 [医药卫生—药品]
  • 相关文献

参考文献30

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J C1in,2011,61(2) :69-90.
  • 2邬晓敏,章烨,朱为民,徐敏,朱寿兴.培美曲塞联合顺铂治疗晚期乳腺癌的疗效观察[J].中国癌症杂志,2011,21(2):159-160. 被引量：14
  • 3汪进良,焦顺昌.替吉奥用于非小细胞肺癌治疗的研究及展望[J].中华医学杂志,2010,90(36):2582-2585. 被引量：25
  • 4Muro K, Boku N, Shimada Y, et al. Irinotecan plus S-1 (IRIS) versus fluorouraeil and folinic acid plus irinotecan(FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomlsed phase 2/3 non-inferiority study (FIRIS study) [J].Lancet Oncol,2010,11(9) :853-860.
  • 5Ueno H, Okusaka T, Furuse J, et al. Multieenter phase 1I study of gemcitabine and S-1 combination therapy(GSThera- py) in patients with metastatic pancreatic cancer[J]. Jpn J Clin Oncol,2011,41(8) ..953 958.
  • 6Saito Y,Oshitanai R,Terao M,et al. Post-marketing safety e- valuation of S-1 in patients withinoperable or recurrent breast cancer: especially in patients treated with S-1 1 trastuzumab[J].Jpn J Clin Oncol, 2011,41(9) : 1051-1058.
  • 7Yamamoto Y, Nishimura R, Tanigawa T,et al. Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer- an observational study by the Kumamoto Breast Cancer Cooperative Group (KBCCG) [J]. GanTo Kagaku Ryoho, 2014,41(10) : 1221-1225.
  • 8马培奇.抗肿瘤新药替吉奥钾研究进展[J].中国医药导刊,2007,9(6):499-502. 被引量：54
  • 9Malet-Martino M, Martino R. Clinical studies of three oral- prodrugs of 5-fluorouraeil( capecitabine, UFT, S-1 ) : a review [J]. Oncologist, 2002,7 (4) : 288-323.
  • 10Ito Y,Osaki Y,Tokudome N,et al. Efficacy of S-1 in heavil- ypretreated patients with metastatic breast cancer: cross-re- sistance to capecitabine[J]. Breast Cancer, 2009,16 (2) .. 126.

二级参考文献45

  • 1徐兵河.改变乳腺癌临床实践的重要临床试验的回顾与评述[J].中国癌症杂志,2005,15(5):408-412. 被引量：22
  • 2Malet-Martino M,Martino R.Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine,UFT,S-1):a review.Oncologist,2002,7:288-323.
  • 3Hoff PM.The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines,UFT/leucovorin (ORZEL) and S-1:a review of their clinical development and therapeutic potential.Invest New Drugs,2000,18:331-342.
  • 4Fukushima M,Morita M,Ikeda K,et al.Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors.Int J Mol Med,2003,12:839-844.
  • 5Kaira K,Sunaga N,Yanagitani N,et al.A phase Ⅰ dose-escalation study of S-1 plus carboplatin in patients with advanced non-smallcell lung cancer.Anticancer Drugs,2007,18:471-476.
  • 6Ohba T,Yamasaki T,Endo Y,et al.A phase Ⅰ study of TS-1plus carboplatin in patients with advanced non-small-cell lung cancer.J Chemother,2009,21:80-85.
  • 7Chikamori K,Kishino D,Takigawa N,et al.A phase Ⅰ study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer.Lung Cancer,2008,62:126-132.
  • 8Kaira K,Sunaga N,Yanagitani N,et al.Phase Ⅰ study of oral s1 plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.Int J Radiat Oncol Biol Phys,2009,75:109-114.
  • 9Ishimoto O,Ishida T,Honda Y,et al.Phase Ⅰ study of daily S-1 combined with weekly irinotecan in patients with advanced nonsmall cell lung cancer.Int J Clin Oncol,2009,14:43-47.
  • 10Kaira K,Sunaga N,Yanagitani N,et al.Phase Ⅰ trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer.Anticancer Drugs,2008,19:289-294.

共引文献90

同被引文献26

二级引证文献39

药学实践杂志
2015年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部